AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.

Trial Details

NCT ID
NCT07215585
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • AZD0486
  • R-mini-CHOP
Locations (sample)
  • Clayton, Australia|-37.91667,145.11667
  • Macquarie University, Australia
  • Melbourne, Australia|-37.814,144.96332
  • Nedlands, Australia|-31.98184,115.8073
  • Waratah, Australia|-32.90667,151.72647

Key Eligibility Criteria

  • Participants are either 80 years of age or older, OR 65 to 79 years of age or older and classified as unfit per sGA, and otherwise not considered c…
  • Histologically confirmed diagnosis of previously untreated LBCL as per WHO-HEM5 (excluding plasmablastic lymphoma) and follicular large cell lymphoma;
  • FDG-avid and measurable disease as per Lugano and Ann Arbor staging;
  • Stage I bulky (7.5 cm and greater) to Stage IV;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →